Clinical Trial Transparency | KU��? Pharmaceuticals

Our Science

ALNYLAM POLICY ON CLINICAL TRIAL TRANSPARENCY

Our Commitment

At KU��, innovative science focused on helping patients is at the core of who we are, and trust, honesty, and integrity are deeply important to how we operate. As an extension of our company culture, KU�� believes that timely disclosure of clinical study information is important to help advance medical research, inform participants and physicians, and engender greater public confidence in the safety of investigational and approved medicines.

KU�� is committed to complying with applicable national and international laws, regulations, and principles for clinical trial disclosure and transparency, including those put forth by industry associations and supported by independent research organizations and editors of leading peer-reviewed journals. KU�� believes that sharing of clinical trial information should be done in a manner that:

Ensures patient confidentiality and privacy
Complies with informed consent given by trial participants
Respects the integrity of national regulatory systems in making benefit-risk decisions in access to products
Preserves the integrity of our research, our commercially confidential information, and our intellectual property
Encourages continued investment in biomedical research that advances public health

The below outlines KU��s policy on Clinical Trial Transparency and the framework we follow in sharing clinical trial information with trial participants, family members and other caregivers, physicians, regulators, and independent researchers. We will continue to review and update this policy where appropriate as transparency regulations change and needs for open data sharing evolve.

Transparency Activities at KU��

Clinical Trial Registration

KU�� registers clinical trial information for KU��-sponsored Phase I-IV clinical studies on , , and other registry websites in compliance with applicable global, regional, and local regulations and industry association principles. In addition, we voluntarily register and provide study information on healthy volunteer studies, observational trials, and expanded access programs on and the .

Results Summaries to Clinical Trial Registries

The posting of summary results of KU��-completed trials to clinical trial registries is a fundamental element of our policy on clinical trial transparency. Summary results for all KU�� interventional clinical trials, in accordance with applicable transparency laws and regulations, are made available on publicly accessible clinical trial registries such as and the ,?as well as local country registries where required (e.g., Spain REEC, Japan JAPIC). These results are reported regardless of the outcome of?the trial.

Plain Language Summaries of Results and Return of Results to Patients

KU�� is committed to providing trial summaries in an easy-to-understand format (referred to as plain language or lay language) to our trial participants, regulatory agencies, and the general public.

Publication in Peer-Reviewed Venues

KU�� submits manuscripts for publication in peer-reviewed scientific and medical journals, which are subject to the peer-review process at the discretion of the journal editors. KU�� will continue to ensure that summaries of clinical trial results of significant importance are submitted for consideration as abstracts during congresses and/or for publication in peer-reviewed journals, regardless if the results of the study are positive or negative. This includes results from studies with investigational medicines whose development programs were discontinued.

Data Sharing with Researchers

KU��s commitment to transparency includes establishing a mechanism for sharing de-identified patient-level datasets with qualified scientific and medical researchers. KU�� has joined the Vivli consortium, an independent, nonprofit organization that has developed a global data-sharing and analytics platform. Qualified researchers can make requests for anonymized clinical trial data from in-scope studies on approved products through . For more information on our data-sharing scope and policy, visit the Vivli website, or contact us at datasharing@alnylam.com.

Custom Body Class

trials

KU����